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ABSTRACT
MicroRNA regulation of developmental and cellular processes is a relatively new field of study, and the available research data
have not been organized to enable its inclusion in pathway and network analysis tools. The association of gene products with
terms from the Gene Ontology is an effective method to analyze functional data, but until recently there has been no
substantial effort dedicated to applying Gene Ontology terms to microRNAs. Consequently, when performing functional
analysis of microRNA data sets, researchers have had to rely instead on the functional annotations associated with the genes
encoding microRNA targets. In consultation with experts in the field of microRNA research, we have created comprehensive
recommendations for the Gene Ontology curation of microRNAs. This curation manual will enable provision of a high-quality,
reliable set of functional annotations for the advancement of microRNA research. Here we describe the key aspects of the
work, including development of the Gene Ontology to represent this data, standards for describing the data, and guidelines to
support curators making these annotations. The full microRNA curation guidelines are available on the GO Consortium wiki
(http://wiki.geneontology.org/index.php/MicroRNA_GO_annotation_manual).
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INTRODUCTION
The past two decades of research have established that
microRNAs (miRNAs) play a central role in regulating the
stability and expression of messenger RNAs (mRNAs).
These molecules are the focus not only of intensive basic re-
search to better define their roles in regulating and integrat-
ing biological processes, but also of applied studies to exploit
their potential value as biomarkers and therapeutic agents
(Janssen et al. 2013; Caputo et al. 2015; Emanueli et al.
2015). MiRNAs are∼22-nucleotide (nt) sequences that func-
tion by forming duplexes with their mRNA targets. The tar-
geted mRNA can be regulated, or “silenced,” by a variety of
mechanisms including reduction of mRNA translation,
mRNA cleavage or promotion of mRNA degradation via
deadenylation (Filipowicz et al. 2008).
MiRNAs have also been shown to activate a gene’s expres-
sion (Zhang et al. 2014), although there is limited support for
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this and it remains to be seen whether this is a common event.
More than 2500 mature human miRNAs have been identifi-
ed so far according to miRBase assembly version GRCh38
(Kozomara and Griffiths-Jones 2014), each of which can tar-
get multiple mRNAs and can have different effects on differ-
ent targets. MiRNA interactions can therefore potentially
define networks of coordinately regulated genes and suggest
novel molecular strategies for integrating and modulating
cellular processes. Studies of miRNAs have been carried out
by many independent groups using diverse experimental
strategies, and integration of the resulting data is difficult.
Even the identification of all mRNAs that can bind a given
miRNA to form a stable duplex under physiological condi-
tions is difficult given the range of approaches used and the
variable data quality. This problem is reflected in miRNA da-
tabases where targets of miRNAs can frequently be reported
based on weak or nonexistent evidence. For example, often
the cited paper does not provide a rigorous experimental
validation, or the miRNA:mRNA association is based on an
unsound inference from a text-mining algorithm. These in-
accuracies and weak inferences impede data mining and inte-
gration efforts (Kalea et al. 2015).
The Gene Ontology (GO) has been successfully applied
to organize similarly complex catalogs of proteins and to im-
pose quality, reliable standards on their annotation (Huang
et al. 2009; Alam-Faruque et al. 2011; Mutowo-Meullenet
et al. 2013). GO annotation condenses experimental data
from peer-reviewed articles into a resource that is easily ac-
cessible by both scientists investigating small data sets and
bioinformaticians performing complex computational analy-
ses (Ashburner et al. 2000). An especially useful application
of GO is functional analysis, or “GO term enrichment,”
which can be used to identify pathways and processes that
are significantly over- or underrepresented for a list of genes,
e.g., differentially expressed genes from a microarray experi-
ment (Huang et al. 2009). Currently, functional analyses of
miRNAs or miRNA high-throughput data sets commonly
use the GO annotations associated with the genes or gene
products the miRNAs are predicted to regulate (e.g., see anal-
yses in Liu et al. 2010; Soh et al. 2013). Since each miRNA
may target up to several thousand mRNAs, each one poten-
tially playing roles in multiple physiological processes, the in-
terpretation of such analyses can be misleading. It was
recently demonstrated by Bleazard and colleagues that terms
FIGURE 1. Ancestor chart from QuickGO showing the child terms of “gene silencing by miRNA” (GO:0035195, all highlighted with gray boxes), as
well as some of the ancestor terms in this part of the ontology.
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668 RNA, Vol. 22, No. 5
 Cold Spring Harbor Laboratory Press on May 19, 2016 - Published by rnajournal.cshlp.orgDownloaded from 
enriched when using functional annotation of miRNA targets
do not remain significant when target distribution bias is cor-
rected (Bleazard et al. 2015). More informative results should
be gained by using the experimentally validated functional
annotations of the miRNAs in analyses. Here we describe
the development of standards to ensure a consistent approach
to the GO annotation of miRNAs and their targets. This in-
cludes the development of ontology terms to represent cur-
rent knowledge, standards for describing the published data
and guidelines to support curation of this data. The field of
miRNA biology continues to develop very rapidly at both a
technical and conceptual level; to accommodate this we
have focused on a framework that will handle current data
types and the development of open-ended and extensible
standards appropriate for additional classes of molecules,
molecular functions, and biological processes.
RESULTS
Ontology development
The GO and its associated annotations are continually evolv-
ing as biological knowledge increases and as curators focus on
annotation and ontology development efforts in specific areas
of biological interest (The Gene Ontology Consortium 2014).
No dedicated effort had focused on the functional curation of
miRNAs, or their biogenesis, and the ontology representing
gene silencing by miRNA was consequently outdated and in-
complete. For example, fundamental terms were absent from
GO including a biological process (BP) term to describe one
of the three common mechanisms of miRNA gene silencing
—via the 3′ UTR by deadenylation. Figure 1 shows how these
three common mechanisms are now represented in GO.
In some cases, existing terms were defined based on outdated
knowledge. For example, the BP term “gene silencing”
(GO:0016458) was originally defined as “Any transcriptional
or post-transcriptional process carried out at the cellular level
that results in long-term gene inactivation”; referring here to
inherited silencing of genes.However,miRNA-regulated gene
silencing is not long-term inactivation, and after consultation
the definition of this term was broadened to: “Any process
carried out at the cellular level that results in either long-
term transcriptional repression via action on chromatin
structure or RNA mediated, post-transcriptional repression
of gene expression.” The ontology was revised and updated
in line with current knowledge prior to creation of the cura-
tion guidelines. So far, 11 new terms related to miRNA bio-
genesis and miRNA-dependent gene silencing have been
created (Table 1) and a number of changes to ontology struc-
ture and term definitions have been made.
Curation guidelines
Curating proteins involved in miRNA biogenesis
The current knowledge representing miRNA biogenesis was
reviewed and presented as a summary in the right-hand
TABLE 1. New miRNA-related GO terms added to the ontology during the course of this project
Name Identifier Definition
Pre-miRNA transporter activity GO:0090631 Enables the directed movement of pre-miRNAs between the nucleus and
the cytoplasm of a cell.
miRNA transporter activity GO:0061717 Enables the directed movement of cleaved miRNAs between the nucleus
and the cytoplasm of a cell.
miRNA export from nucleus GO:0061716 The directed movement of a processed miRNA from the nucleus to the
cytoplasm.
Double-stranded miRNA binding GO:0098851 Interacting selectively and noncovalently with double-stranded miRNA.
Double-stranded miRNA is formed by processing of pre-miRNA stem-
loop structures.
miRNA 2′-O-methylation GO:0061715 The post-transcriptional addition of a methyl group to the 2′ oxygen atom
of a nucleotide residue in an miRNA molecule.
Endoribonuclease activity, cleaving miRNA-
paired mRNA
GO:0090624 Catalysis of the endonucleolytic cleavage of the mRNA in a double-
stranded RNA molecule formed by the base-pairing of an mRNA with an
miRNA.
Regulation of production of miRNAs involved
in gene silencing by miRNA
GO:1903798 Any process that modulates the frequency, rate, or extent of production of
miRNAs involved in gene silencing by miRNA.
Negative regulation of production of miRNAs
involved in gene silencing by miRNA
GO:1903799 Any process that stops, prevents, or reduces the frequency, rate, or extent
of production of miRNAs involved in gene silencing by miRNA.
Positive regulation of production of miRNAs
involved in gene silencing by miRNA
GO:1903800 Any process that activates or increases the frequency, rate, or extent of
production of miRNAs involved in gene silencing by miRNA.
Deadenylation involved in gene silencing by
miRNA
GO:0098806 Shortening of the poly(A) tail of a nuclear-transcribed mRNA following
miRNA binding to mRNA, resulting in destabilization of the mRNA and
a reduction in the efficiency of its translation.
mRNA cleavage involved in gene silencing GO:0098795 Cleavage of an mRNA occurring as part of the mechanism of gene
silencing.
Gene Ontology curation of microRNAs
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panels of Figure 2 (animal pathway) and Figure 3 (plant path-
way). A description of the miRNA biogenesis pathway will
not be covered here as it has been described extensively else-
where, (e.g., Filipowicz et al. 2008; Axtell et al. 2011; Xie et al.
2015). Additionally, the pathway can be viewed interactive-
ly at Reactome (http://www.reactome.org/PathwayBrowser/
#DIAGRAM=211000&ID=203927&PATH=74160) and the
Rat Genome Database (http://rgd.mcw.edu/rgdweb/pathway/
pathwayRecord.html?acc_id=PW:0000808). The GO terms
applicable to each of the protein compo-
nents or complexes to capture their role
in miRNA biogenesis are presented in the
left-hand panel of Figures 2 and 3. These
terms do not provide comprehensive an-
notation of these proteins, many of which
are also involved in other pathways.
Curating the role of miRNAs in gene
silencing
Depending on the evidence presented in
apublication, thereareseveralwaystorep-
resent the roles of an miRNA in gene si-
lencing. To assist biocurators in selecting
the correct GO terms for annotation,
we have provided a decision tree for the
different types of evidence presented by
authors that can be used to support differ-
ent gene silencing roles (Fig. 4). Briefly, if
binding of the miRNA to the mRNA is
demonstrated followed by a reduction in
mRNA levels, for example, by showing
thatapplicationof themiRNAtothe target
mRNA3′UTRfused toa luciferasereport-
er results in decreased reporter expression
while application to a mutated form of
the 3′ UTR has no effect (Clément et al.
2015), the miRNA should be annotated
to the molecular function (MF) term
“mRNA binding involved in post-tran-
scriptional gene silencing by miRNA”
(GO:1903231). If binding is not demon-
strated but there is evidence of a reduc-
tion in the levels of an mRNA in
responsetoanmiRNA,forexample,anex-
periment showing that application of a
given miRNA results in decreased target
mRNA levels as measured by qRT-PCR
(e.g., seeMaegdefessel et al. 2012), thenei-
ther the BP term “negative regulation of
gene expression” (GO:0010629) should
be used (if the mRNA is not a predicted
target) or “gene silencing by miRNA”
(GO:0035195, if the mRNA is a predicted
target). In each case, the target mRNA
must be indicated within the annotation, as detailed in the an-
notation examples in the section “Curating themRNA targets
of miRNAs” and in Figure 4. In certain circumstances, when
the authors have shown the exact mechanism of silencing, i.
e., translational repression, deadenylation ormRNA cleavage,
it is possible to use the child terms of the BP term “gene silenc-
ing by miRNA” as indicated in the following sections.
Translational repression. If there is sufficient evidence to
show the miRNA is involved in translational repression of
FIGURE 2. The canonical animal miRNA processing pathway (right panel) and the GO terms
that are expected to be associated with the protein components of this pathway (left panel).
Association of these GO terms will depend on the experimental evidence available; unrelated
or more specific GO terms may be associated to these gene products if appropriate evidence is
available. “contributes_to” is a qualifier used in GO annotation to indicate the entity annotated
does not perform the molecular function in isolation, but as a member of a complex. Protein
names: (DROSHA) Ribonuclease 3; (DGCR8) Microprocessor complex subunit DGCR8;
(XPO-5) Exportin-5; (RAN-GTP) GTP-charged Ran GTPase; (DICER1) Endoribonuclease
Dicer; (TARBP2) RISC-loading complex subunit TARBP2; (AGO) Argonaute.
Huntley et al.
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the mRNA target, then the GO BP term “miRNA-mediated
inhibition of translation” (GO:0035278) should be used.
For example, application of mouse miR-1 leads to a decrease
in the protein level of histone deacetylase 4 (HDAC4), but has
no effect on the level of mRNA encoding this protein (Chen
et al. 2006).
mRNA deadenylation. The GO BP term “deadenylation
involved in gene silencing by miRNA” (GO:0098806) should
be used if there is sufficient evidence to
show the miRNA is involved in deadeny-
lation of the mRNA target. This GO term
was associated with the Drosophila
miRNA Let-7 based on experiments de-
scribed by Wakiyama et al. (2007). In
these experiments, the length of the
poly(A) tail of a luciferase reporter
mRNA containing six Let-7 target se-
quences was reduced to almost the
same length as the nonadenylated control
mRNA following treatment with Let-7,
while a control containing mutated Let-
7 sequences was unaltered.
mRNA cleavage. If there is sufficient
evidence to show the miRNA is involved
in cleavage of the mRNA target, the GO
BP term “mRNA cleavage involved
in gene silencing by miRNA” (GO:
0035279) should be used. For example,
Wang and Guo (2015) detected a specific
cleavage site within the mRNA of the
Arabidopsis auxin responsive protein
IAA28, by a 5′ RACE assay and subse-
quent sequencing, following application
of Arabidopsis miRNA-847.
Curating the mRNA targets of
miRNAs
One of the main criteria for an mRNA to
be targeted by an miRNA is perfect or
near-perfect complementarity to the 5′
end of the miRNA, the so-called “seed re-
gion” at positions 2 to 7, but this is not
the only determinant (Betel et al. 2010).
The other determinants used by compu-
tational algorithms to predict targeted
mRNAs, with varying success, include se-
quence alignment and conservation,
mRNA secondary structure analysis and
calculation of hybridization energy
(Grimson et al. 2007; Betel et al. 2008;
Wang and El Naqa 2008). However,
even if an mRNA is a predicted target
of an miRNA, it is not certain that it
will be a target in vivo. It is therefore im-
portant to distinguish between real tar-
gets and potential targets, which is only possible by
experimental investigation. An increasing number of experi-
mental methods are available for testing either the binding or
the regulation aspects of miRNA:mRNA functional interac-
tion, some of which are classified as high-throughput
(HTP) (Thomson et al. 2011; Chou et al. 2015). To assist bio-
curators in deciding if the evidence for an miRNA:mRNA
functional interaction is sufficient to create an annotation
FIGURE 3. The canonical plant miRNA processing pathway (right panel) and the GO terms that
are expected to be associated with the protein components of this pathway (left panel).
Association of these GO terms will depend on the experimental evidence available; unrelated
or more specific GO terms may be associated to these gene products if appropriate evidence is
available. Protein names: NOT2B: NEGATIVE ON TATA-LESS 2B; CDC5: CELL DIVISION
CYCLE 5; Mediator complex proteins (includes: MEDIATOR14, MEDIATOR20a,
MEDIATOR20b, MEDIATOR20c, MEDIATOR21, MEDIATOR25); miPEP: miRNA encoded
peptide; DCL1: DICER-LIKE 1; SE: SERRATE; HYL1: HYPONASTIC LEAVES 1; DDL:
DAWDLE; TGH: TOUGH; CBP20: CAP BINDING COMPLEX PROTEIN 20; CBP80: CAP
BINDING COMPLEX PROTEIN 80; HEN1: HUA ENHANCER 1; HST: HASTY; HSP90:
HEAT SHOCK PROTEIN 90; SQN: SQUINT; AGO: ARGONAUTE.
Gene Ontology curation of microRNAs
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we have provided a list of commonly reported methodologies
in the online miRNA curation guidelines. This includes a de-
scription of the method and whether it is sufficient on its own
to demonstrate the binding and regulation aspects or whether
additional experimental evidence is required. We recom-
mend that in cases which combine two methods for demon-
strating functional interaction, only one of these should be a
HTPmethod as indicated on the list; as technologies improve
this decision may be revisited. For example, a reporter assay
alone is sufficient to demonstrate binding to and regulation
of the mRNA, but a CLASH experiment (HTP) can only
demonstrate binding of the miRNA:mRNA; therefore, addi-
tional non-HTP evidence demonstrating the regulation of the
mRNA levels is also required, such as a qRT-PCR. For the
purpose of determining how a target should be captured by
GO annotation, we have defined three categories of mRNA
target according to what evidence is available for the associ-
ation as follows:
Predicted targets. A predicted target is an mRNA that has a
3′ UTR sequence predicted to contain the binding site(s)
of the miRNA. Targets are predicted in silico using sophisti-
cated algorithms (Ekimler and Sahin 2014; Afonso-Grunz
and Müller 2015). Predicted targets are not captured as
GO annotations but are used to inform the GO term that
should be used for validated “other” targets (see below and
Fig. 4).
Validated binding targets. A validated binding target is an
mRNA that has undergone experimental investigation to
determine that the miRNA both binds to and regulates the
expression of the mRNA. The most applicable evidence is a
reporter assay, where the miRNA is combined with a report-
er-fused 3′ UTR of the mRNA and altered levels of reporter
expression are observed (Clément et al. 2015). Also accept-
able is an assay demonstrating physical interaction between
the miRNA:mRNA, e.g., affinity purification, together with
an assay demonstrating that the miRNA alters the levels of ei-
ther the mRNA (e.g., qRT-PCR) or protein (e.g., Western
blot) (Dangwal et al. 2012). It must be noted, however, that
these methods only provide an indication that the miRNA
is able to bind the mRNA not that it will bind in a physiolog-
ical context, where there may not be coincident expression of
the miRNA and mRNA and also where the concentrations
and stoichiometry of the miRNA and mRNA may be
different.
FIGURE 4. Decision tree for selecting the GO terms and annotation extensions used for capturing targets of miRNAs. The types of evidence in the
blue boxes are described further in the online guidelines. A reporter assay, or an affinity purification together with an assay demonstrating an effect of
the miRNA onmRNA levels, is sufficient to classify a target as “validated binding”; additional evidence that the target is predicted for the miRNA does
not affect the annotation applied, therefore this option is not shown. Author justification means the author indicates why this mRNA is an expected
target or shows an effect on an expected downstream process. (HTP) High-throughput method, (pSILAC) pulsed stable isotope labeling by amino
acids in cell culture.
Huntley et al.
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Validated “other” targets. A validated “other” target is an
mRNA that has undergone experimental investigation to
demonstratemiRNA regulation of the target, but has not con-
clusively been shown to bind to the miRNA. Assays that dem-
onstrate this include western blot, qRT-PCR, or pSILAC
(Dangwal et al. 2012).
This classification enables biocurators to decide which GO
terms and associated information can be applied to the
miRNA:mRNA pairing. To assist biocurators further, the de-
cision tree (Fig. 4) uses experimental assays as the deciding
factors for building an accurate annotation. To maintain a
high-quality, reliable resource for miRNA target data, we
only curate experimentally validated targets from peer-re-
viewed publications.
Annotation extensions provide a mechanism to associate
additional information with a GO term (Huntley et al.
2014), and are used to capture miRNA target genes (illustrat-
ed in Fig. 4). Depending on the available experimental data,
with GO annotations we can distinguish between targets that
are bound by themiRNA and those where there is insufficient
evidence to demonstrate direct binding. AnmRNA target that
is experimentally demonstrated tobind themiRNA, leading to
its reduced expression (validated binding) can be annotated as
follows:16
Annotation 1
Object: human miR-21 (RNACentral:URS000039ED8D_
9606)
GO term: gene silencing by miRNA (GO: 0035195)
Annotation Extension: regulates_expression_of human SPRY2
gene (Ensembl:ENSG00000136158)
Reference: PubMed:23239100
Annotation 2
Object: human miR-21 (RNACentral:URS000039ED8D_
9606)
GO term: mRNA binding involved in post-transcriptional
gene silencing (GO:1903231)
Annotation Extension: has_direct_input human SPRY2 gene
(Ensembl:ENSG 00000136158)
Reference: PubMed:23239100
Combined, these annotations mean that human miR-21
can bind the SPRY2 mRNA causing silencing of the gene’s
expression.
AnmRNA target that is experimentally demonstrated to be
a target of the miRNA, but for which there is insufficient ev-
idence to show that it binds the miRNA (validated other), can
be annotated as follows:
Object: human miR-200b (RNACentral:URS000014D9C1_
9606)
GO term: gene silencing by miRNA (GO: 0035195)
Annotation Extension: regulates_expression_of human
PTPN12 gene (Ensembl:ENSG00000127947)
Reference: PubMed:16762633
This annotation means that human miR-200b silences ex-
pression of PTPN12 but the molecular mechanism of silenc-
ing has not been established. As noted earlier, if the exact
mechanism of silencing is shown experimentally the child
terms of “gene silencing by miRNA,” e.g., “deadenylation in-
volved in gene silencing by miRNA,” should instead be used
(Fig. 1).
Capturing the context of gene silencing
Each miRNA can have hundreds of predicted targets depend-
ing on the cell or tissue type, or developmental stage of the
organism. Therefore, themiRNAmay have different available
targets and different biological roles depending on the con-
text of its expression. We can capture this contextual infor-
mation in the GO annotations using annotation extensions.
Mouse miR-29b, for example, was shown to reduce the
mRNA levels of elastin through use of an miRNA mimic
that increased levels of miR-29b in smooth muscle cells, a
cell type known to express miR-29b (Zampetaki et al.
2014). The GO annotation created is:
Object: mouse miR-29b (RNACentral:URS000024463E_
10090)
GO term: gene silencing by miRNA (GO:0035195)
Annotation Extension: regulates_expression_of mouse ELN
gene (Ensembl:ENSMUSG00000029675), occurs_in smooth
muscle cell (CL:0000192)
Reference: PubMed:25201911
This annotation is interpreted as: mouse miR-29b is in-
volved in gene silencing of mouse ELN in smooth muscle
cells. Providing these contextual details within the GO anno-
tation will assist researchers wishing to perform cell- or tis-
sue-specific network analyses.
Capturing the downstream effects of gene silencing
Amajor use of GO is large-scale analysis of gene function, for
example GO term enrichment. Analysis of miRNA data sets
will be improved, therefore, by curating the consequential ef-
fects of specific miRNAs on the cell or organism, i.e., the
physiological processes regulated by the silencing event. By
way of example, Castaldi et al. (2014) demonstrated that
mouse miR-133a could silence expression of the adenylate
cyclase ADCY6 gene. The authors went on to show the effect
that this silencing had on cardiac muscle cells: the enzyme ac-
tivity of the adenylate cyclase and rate of cAMP accumulation
were reduced. This observation is captured in the following
annotation:
16Note that in actual GO annotations, only the database identifiers are used for curated
entities and GO terms, not textual names included here for illustration purposes (see
Materials and Methods for more details).
Gene Ontology curation of microRNAs
www.rnajournal.org 673
 Cold Spring Harbor Laboratory Press on May 19, 2016 - Published by rnajournal.cshlp.orgDownloaded from 
Object: mouse miR-133a (RNACentral:URS00004C9052_
10090)
GO term: negative regulation of adenylate cyclase activity
(GO:0007194)
Annotation Extension: occurs_in cardiac muscle cell (CL:
0000746)
Reference: PubMed:24807785
This annotation is interpreted as: mouse miR-133a is in-
volved in the attenuation of adenylate cyclase activity in car-
diac muscle cells. Note: Because the authors measured total
adenylate cyclase activity, not specifically ADCY6, it is not
possible to add ADCY6 as the target of the regulation.
It is important to note that if the authors state that
the miRNA is being expressed in cells/tissues where it would
not normally be expressed, the experiment is not physiolog-
ically relevant information—miRNAs are known to have
different targets in different cell and tissue types (Zhu et al.
2011)—so it would not be appropriate to create an
annotation.
The inclusion of such biologically relevant effects of
miRNA gene silencing in the GO annotation data set will
enable researchers to perform functional enrichment on
the annotations that are associated directly with miRNAs,
allowing more reliable and significant interpretations of
large-scale data.
Evidence codes
Evidence codes are used in GO annotation to indicate the
type of evidence that is available in a paper to support the as-
sociation of a GO term with a gene product (Balakrishnan
et al. 2013). The use of evidence codes for curation of
miRNAs follows the GOC guidelines (http://geneontology.
org/page/guide-go-evidence-codes). Generally, there are
two types of experiments used when investigating the role
of an miRNA: (i) increasing the amount of miRNA, or (ii)
decreasing the amount or effectiveness of an miRNA. The ev-
idence code used will therefore be based on which type of
modulation is applied (see van Rooij et al. 2008 for a review
of miRNA modulations): (i) When increasing the amount of
miRNA, e.g., by using a pre-miRNA, the miRNA should be
annotated using “inferred from direct assay” (IDA); this is
because the sequence is unchanged and these experiments
can provide valuable information about the normal, in vivo
function of the miRNA. If an over-expression of an
miRNA clearly results in a gain-of-function that is not phys-
iologically relevant, this is not curated. (ii) When decreasing
the amount of miRNA or inhibiting its activity, e.g., by using
an antagomir or mutating the sequence, the miRNA should
be annotated using the “inferred from mutant phenotype”
(IMP) evidence code; this is because the cellular effect of
“disturbing” the normal functioning of the miRNA is used
to make an inference about the normal, in vivo function of
the miRNA.
Inferring knowledge from other species
In the absence of experimental data for a particular species, a
common practice in GO is to make an annotation based on
sequence similarity or orthology using the evidence codes in-
ferred from structural or sequence similarity (ISS) or inferred
from sequence orthology (ISO) (Balakrishnan et al. 2013).
Caution must be used by any curator wishing to infer knowl-
edge about the function of an miRNA in one species from ex-
perimental data for an miRNA from another species. This is
because even slight variations in the sequences of the mRNA
or miRNA can cause loss of complementarity and disruption
of the interaction, as demonstrated when using a mutated
form of either the miRNA or mRNA in a standard reporter
assay used to validate targets of miRNAs (Clément et al.
2015). Individual annotation groups will have different poli-
cies with respect to whether or not annotations are trans-
ferred to miRNAs from other species.
Summary
MiRNA annotations should minimally aim to capture (i) the
miRNA’s main role in gene silencing and its target(s),
e.g., “gene silencing by miRNA” with the target gene in the
annotation extension field, and (ii) the effect of silencing
the target mRNA, e.g., “negative regulation of adenylate cy-
clase activity.”
DISCUSSION
Resources for analyzing miRNA functional information are
currently restrictive for downstream analysis. Here we
describe the curation of functional data to support miRNA
research, providing scientists access to high-quality, reliable
data with which to inform their hypotheses and plan future
experiments. Over time, these guidelines applied to miRNA
annotation will provide miRNA target information that is
easy to navigate to identify the experimentally validated tar-
gets of a particular miRNA. Contextual information provides
experimentally verified links between miRNAs and other
physiological information that is crucial for accurate analysis
of pathway and network data (Khatri et al. 2012). Annotation
of regulated processes directly to the miRNA will enable rel-
evant functional analyses, such as GO term enrichment. Just
as GO protein annotation strategies have been applied to
link pathway databases such as Reactome to the GO frame-
work, the miRNA annotation strategy outlined here will en-
able miRNA annotation to be similarly utilized, e.g., for the
Reactome Pre-NOTCH transcription and translation path-
way http://www.reactome.org/PathwayBrowser/#/R-HSA-
1912422&SEL=1912408&PATH=R-HSA-162582,R-HSA-
157118. These guidelines are publicly available and for use by
any scientist wishing to describe the roles of miRNAs and
submit annotations to the GO Consortium. Adoption of
these guidelines will allow biocurators to build valuable re-
sources useful to the wider scientific community. We will
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continue refining these guidelines accordingly as new knowl-
edge is obtained.
We encourage contributions of miRNA GO annotations
for inclusion into the GO Consortium database; contact
the GO helpdesk (http://geneontology.org/form/contact-go)
for more information about the tools available to support
miRNA annotation and the required format of submitted an-
notations.
MATERIALS AND METHODS
Functional annotation
We describe the functional annotation of miRNAs and proteins us-
ing the GO vocabulary. The workflow for the general functional
curation of gene products is published elsewhere and provides a use-
ful guide for basic GO annotation techniques (Balakrishnan et al.
2013). The current article describes only the key aspects of curating
miRNAs, the full miRNA curation guidelines are available on the
GO Consortium wiki (http://wiki.geneontology.org/index.php/
MicroRNA_GO_annotation_manual).
Ensuring correct representation of current knowledge
by expert biocuration
To ensure that a reliable source of functional data is maintained for
miRNA research, we recommend that curation of miRNAs is based
on experimental data from peer-reviewed journals. Even when using
such high-quality experimental data, the translation of biological
knowledge into GO annotation can be challenging, especially in
such a new and rapidly evolving field of research. During this proj-
ect, we have updated the ontology with current knowledge—where
necessary working with experts in the field to establish correct def-
initions and placement of terms within the ontology. Using the im-
proved ontology we have begun to fill in gaps in annotations and to
correct any errors that may exist.
Defining the scope of the guidelines
To give a full picture of regulation of gene expression by miRNAs,
from their initial transcription to their roles in gene silencing, we
first make recommendations for the curation of the protein compo-
nents of the canonical miRNA biogenesis pathways in animals and
plants. We then proceed to provide recommendations for curation
of the miRNAs’ roles in gene regulation. As research progresses,
alternative mechanisms of miRNA regulation are being discovered
(Filipowicz et al. 2008; Hausser et al. 2013; Wilczynska and
Bushell 2014; Zhang et al. 2014). Here we focus on the best-studied
mechanism: the effect of miRNAs on gene silencing via the 3′ UTR
of mRNAs. We curate only miRNAs that are experimentally verified
as involved in gene silencing and include their validated gene targets,
ensuring we maintain a high-quality and reliable resource. We cap-
ture the experimentally demonstrated effect of the specific genes’ si-
lencing on the cell or organism by annotating the miRNA directly
with the relevant GO BP terms, something that has not been provid-
ed in other resources to date but that is critical information for un-
biased functional analyses. We describe how contextual data for the
roles of miRNAs are captured, including cell or tissue types. Further
details on using annotation extensions to capture contextual data are
available in Huntley et al. (2014).
Database identifiers
The recommendeddatabase identifier formiRNAs inGOannotation
are those provided by RNAcentral (The RNAcentral Consortium
2015), e.g., URS000039ED8D_9606 for human miR-21. Any stable
identifier, e.g., Model Organism Database or Ensembl, may be used
for the mRNA target gene. Here we have used Ensembl gene identi-
fiers for the regulated gene, e.g., Ensembl:ENSG00000136158 for hu-
man SPRY2 gene.
ACKNOWLEDGMENTS
R.P.H. and R.C.L. are supported by funding from a British Heart
Foundation grant (RG/13/5/30112) and the National Institute for
Health Research University College London Hospitals Biomedical
Research Centre. M.M. is a Senior Research Fellow of the British
Heart Foundation (FS/13/2/29892). A.Z. is an Intermediate Fellow
of the British Heart Foundation (FS/13/18/30207). D.S. is supported
bya grant awarded to theMouseGenomeDatabase fromtheNational
Human Genome Research Institute at the US National Institutes of
Health (HG-00330). P.D’E., M.G., M.O.-M. are supported by grants
from the US National Institutes of Health (P41 HG003751 and U54
GM114833), Ontario Research Fund, and the European Molecular
Biology Laboratory. D.H. is supported by a grant awarded to the
Zebrafish Information Network from the National Human
Genome Research Institute at the US National Institutes of Health
(HG002659). A.Z.K. is funded by an NIHR University College
London Hospitals Biomedical Research Centre, Research Capability
Funding award (RCF) (RCF123). L.M. is a Ragnar Söderberg fellow
in Medicine (M-14/55) and received funding from Swedish Heart-
Lung-Foundation (20120615, 20130664, 20140186). R.B., D.O-S.,
and K.V.A. are supported by a grant awarded to The Gene Ontology
Consortium (Principal Investigators: J.A. Blake, J.M. Cherry, S.E.
Lewis, P.W. Sternberg, and P.D. Thomas) by the National Human
Genome Research Institute (NIH-NHGRI HG002273). V.P. and J.
R.S. are supported by a grant from the National Heart, Lung, and
Blood Institute on behalf of the National Institutes of Health
(HL64541). V.W. is supported by a Wellcome Trust grant (104967/
Z/14/Z). We would like to thank Leonore Reiser and Tanya
Berardini who provided guidance on the plant miRNA processing
pathway. Also thanks to David Hill, Harold Drabkin, Judith Blake,
Karen Christie, Donghui Li, and Pascale Gaudet who contributed to
discussions regarding GO curation procedures and to Lisa
Matthews and Bruce May who provided helpful feedback on the
manuscript. We are very grateful to Tony Sawford and Maria
Martin from the European Bioinformatics Institute for access to the
online GO curation tool, which is an essential component of this an-
notation project.Many thanks tomembers of theGOEditorialOffice
for useful discussions about the placement and definition of newGO
terms. We also thank Alex Bateman and Anton Petrov for being re-
sponsive to our feedback regarding RNAcentral functionality.
Author contributions: R.C.L. initiated discussions in the GO
Consortium regarding miRNA curation guidelines and supervised
the project; R.P.H. researched and constructed the guidelines and
wrote the manuscript; R.P.H., R.C.L., D.S., R.B., P.D’E., M.G., M.
O-M., D.H., V.P., J.R.S., K.V.A., and V.W. contributed to
Gene Ontology curation of microRNAs
www.rnajournal.org 675
 Cold Spring Harbor Laboratory Press on May 19, 2016 - Published by rnajournal.cshlp.orgDownloaded from 
discussions regarding GO curation procedures and provided feed-
back on the manuscript. D.O-S. provided the expertise on defini-
tions and placements of miRNA-related GO terms and performed
the necessary updates and additions to both the GO and to the an-
notation extension relations used herein. M.M., A.Z., L.M., and A.Z.
K. provided guidance with the scientific aspect of the guidelines and
provided feedback on the manuscript.
Received November 19, 2015; accepted January 19, 2016.
REFERENCES
Afonso-Grunz F, Müller S. 2015. Principles of miRNA-mRNA interac-
tions: beyond sequence complementarity. Cell Mol Life Sci 72:
3127–3141.
Alam-Faruque Y, Huntley RP, Khodiyar VK, Camon EB, Dimmer EC,
Sawford T, Martin MJ, O’Donovan C, Talmud PJ, Scambler P,
et al. 2011. The impact of focused gene ontology curation of specific
mammalian systems. PLoS One 6: e27541.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM,
Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. 2000. Gene ontol-
ogy: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet 25: 25–29.
Axtell MJ, Westholm JO, Lai EC. 2011. Vive la différence: biogenesis and
evolution of microRNAs in plants and animals.Genome Biol 12: 221.
Balakrishnan R, Harris MA, Huntley R, Van Auken K, Cherry JM. 2013.
A guide to best practices for Gene Ontology (GO) manual annota-
tion. Database (Oxford) 2013: bat054.
Betel D,WilsonM, GabowA,Marks DS, Sander C. 2008. ThemicroRNA.
org resource: targets and expression.Nucleic Acids Res 36:D149–D153.
Betel D, Koppal A, Agius P, Sander C, Leslie C. 2010. Comprehensive
modeling of microRNA targets predicts functional non-conserved
and non-canonical sites. Genome Biol 11: R90.
Bleazard T, Lamb JA, Griffiths-Jones S. 2015. Bias in microRNA func-
tional enrichment analysis. Bioinformatics 31: 1592–1598.
Caputo M, Saif J, Rajakaruna C, Brooks M, Angelini GD, Emanueli C.
2015. MicroRNAs in vascular tissue engineering and post-ischemic
neovascularization. Adv Drug Deliv Rev 88: 78–91.
Castaldi A, Zaglia T, Di Mauro V, Carullo P, Viggiani G, Borile G, Di
Stefano B, Schiattarella GG, Gualazzi MG, Elia L. 2014.
MicroRNA-133 modulates the β1-adrenergic receptor transduction
cascade. Circ Res 115: 273–283.
Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM,
Conlon FL, Wang DZ. 2006. The role of microRNA-1 and
microRNA-133 in skeletal muscle proliferation and differentiation.
Nat Genet 38: 228–233.
Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, Yang CD,
Hong HC, Wei TY, Tu SJ, et al. 2015. miRTarBase 2016: updates to
the experimentally validated miRNA-target interactions database.
Nucleic Acids Res 44: D239–D247.
Clément T, Salone V, Rederstorff M. 2015. Dual luciferase gene reporter
assays to study miRNA function. Methods Mol Biol 1296: 187–198.
Dangwal S, Bang C, Thum T. 2012. Novel techniques and targets in car-
diovascular microRNA research. Cardiovasc Res 93: 545–554.
Ekimler S, Sahin K. 2014. Computational methods for microRNA target
prediction. Genes 5: 671–683.
Emanueli C, Shearn AIU, Angelini GD, Sahoo S. 2015. Exosomes and
exosomal miRNAs in cardiovascular protection and repair. Vascul
Pharmacol 71: 24–30.
Filipowicz W, Bhattacharyya SN, Sonenberg N. 2008. Mechanisms of
post-transcriptional regulation by microRNAs: are the answers in
sight? Nat Rev Genet 9: 102–114.
The Gene Ontology Consortium. 2014. Gene Ontology Consortium:
going forward. Nucleic Acids Res 43: D1049–D1056.
Grimson A, Farh KK-H, Johnston WK, Garrett-Engele P, Lim LP,
Bartel DP. 2007. MicroRNA targeting specificity in mammals: deter-
minants beyond seed pairing. Mol Cell 27: 91–105.
Hausser J, Syed AP, Bilen B, Zavolan M. 2013. Analysis of CDS-located
miRNA target sites suggests that they can effectively inhibit transla-
tion. Genome Res 23: 604–615.
Huang DW, Sherman BT, Lempicki RA. 2009. Bioinformatics enrich-
ment tools: paths toward the comprehensive functional analysis of
large gene lists. Nucleic Acids Res 37: 1–13.
Huntley RP, Harris MA, Alam-Faruque Y, Blake JA, Carbon S, Dietze H,
Dimmer EC, Foulger RE, Hill DP, Khodiyar VK, et al. 2014. A meth-
od for increasing expressivity of Gene Ontology annotations using a
compositional approach. BMC Bioinformatics 15: 155.
Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M,
Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al. 2013.
Treatment of HCV infection by targeting microRNA. N Engl J
Med 368: 1685–1694.
Kalea AZ, Hoteit R, Suvan J, Lovering RC, Palmen J, Cooper JA,
Khodiyar VK, Harrington Z, Humphries SE, D’Aiuto F. 2015.
Upregulation of gingival tissue miR-200b in obese periodontitis sub-
jects. J Dent Res 94: 59S–69S.
Khatri P, Sirota M, Butte A. 2012. Ten years of pathway analysis: current
approaches and outstanding challenges. PLoS Comput Biol 8:
e1002375.
Kozomara A, Griffiths-Jones S. 2014. miRBase: annotating high confi-
dence microRNAs using deep sequencing data. Nucleic Acids Res
42: D68–D73.
Liu G, Ding M, Chen J, Huang J, Wang H, Jing Q, Shen B. 2010.
Computational analysis of microRNA function in heart develop-
ment. Acta Biochim Biophys Sin (Shanghai) 42: 662–670.
Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, Chin JT, Raaz U,
Schoelmerich AM, Raiesdana A, Leeper NJ, et al. 2012. Inhibition
of microRNA-29b reduces murine abdominal aortic aneurysm de-
velopment. J Clin Invest 122: 497–506.
Mutowo-Meullenet P, Huntley RP, Dimmer EC, Alam-Faruque Y,
Sawford T, Jesus Martin M, O’Donovan C, Apweiler R. 2013. Use
of Gene Ontology Annotation to understand the peroxisome prote-
ome in humans. Database (Oxford) 2013: bas062.
The RNAcentral Consortium. 2015. RNAcentral: an international data-
base of ncRNA sequences. Nucleic Acids Res 43: D123–D129.
Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. 2013.
MicroRNA-30c reduces hyperlipidemia and atherosclerosis in
mice by decreasing lipid synthesis and lipoprotein secretion. Nat
Med 19: 892–900.
Thomson DW, Bracken CP, Goodall GJ. 2011. Experimental strategies
for microRNA target identification.Nucleic Acids Res 39: 6845–6853.
van Rooij E,MarshallWS, Olson EN. 2008. TowardmicroRNA-based ther-
apeutics for heart disease: the sense in antisense. Circ Res 103: 919–928.
Wakiyama M, Takimoto K, Ohara O, Yokoyama S. 2007. Let-7
microRNA-mediated mRNA deadenylation and translational re-
pression in a mammalian cell-free system.Genes Dev 21: 1857–1862.
Wang X, El Naqa IM. 2008. Prediction of both conserved and noncon-
served microRNA targets in animals. Bioinformatics 24: 325–332.
Wang JJ, Guo HS. 2015. Cleavage of INDOLE-3-ACETIC ACID
INDUCIBLE28 mRNA by microRNA847 upregulates auxin signal-
ing to modulate cell proliferation and lateral organ growth in
Arabidopsis. Plant Cell 27: 574–590.
Wilczynska A, Bushell M. 2014. The complexity of miRNA-mediated re-
pression. Cell Death Differ 22: 22–33.
Xie M, Zhang S, Yu B. 2015. microRNA biogenesis, degradation and ac-
tivity in plants. Cell Mol Life Sci 72: 87–99.
Zampetaki A, Attia R, Mayr U, Gomes RSM, Phinikaridou A, Yin X,
Langley SR, Willeit P, Lu R, Fanshawe B, et al. 2014. Role of miR-
195 in aortic aneurysmal disease. Circ Res 115: 857–866.
Zhang Y, Fan M, Zhang X, Huang F, Wu K, Zhang J, Liu J, Huang Z,
LuoH, Tao L, et al. 2014. CellularmicroRNAs up-regulate transcrip-
tion via interaction with promoter TATA-box motifs. RNA 20:
1878–1889.
Zhu W, Yang L, Du Z. 2011. MicroRNA regulation and tissue-specific
protein interaction network. PLoS One 6: e25394.
Huntley et al.
676 RNA, Vol. 22, No. 5
 Cold Spring Harbor Laboratory Press on May 19, 2016 - Published by rnajournal.cshlp.orgDownloaded from 
 10.1261/rna.055301.115Access the most recent version at doi:
 2016 22: 667-676 originally published online February 25, 2016RNA
  
Rachael P. Huntley, Dmitry Sitnikov, Marija Orlic-Milacic, et al. 
  
Ontology
Guidelines for the functional annotation of microRNAs using the Gene
  
References
  
 http://rnajournal.cshlp.org/content/22/5/667.full.html#ref-list-1
This article cites 41 articles, 19 of which can be accessed free at:
  
Open Access
  
 Open Access option.RNAFreely available online through the 
  
License
Commons 
Creative
.http://creativecommons.org/licenses/by/4.0/
(Attribution 4.0 International), as described at 
, is available under a Creative Commons LicenseRNAThis article, published in 
Service
Email Alerting
  
 click here.right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the top
 http://rnajournal.cshlp.org/subscriptions
 go to: RNATo subscribe to 
© 2016 Huntley et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society
 Cold Spring Harbor Laboratory Press on May 19, 2016 - Published by rnajournal.cshlp.orgDownloaded from 
